Chronic Graft-Versus-Host Disease Medication, Niktimvo, Gains FDA Approval
August 15, 2024
This therapy is a first-in-class treatment for chronic graft-versus-host disease, which develops in roughly 42% of those who receive a stem cell of bone marrow transplant.